Equid Herpesvirus type-1 (EHV-1) is one of the most important pathogens infecting horses and other equidae, including donkeys and zebras. This ubiquitous virus continues to cause infectious outbreaks in horses worldwide and there are still many unanswered questions. To name a few: How and where does the virus become latent? What determines exit from latency? How does the virus modulate the immune system to replicate in the host, establish latency, and yield such short-lived immunity after vaccination? How do we predict neuropathogenecity? How do we best treat infected or exposed horses to prevent neurologic disease, neonatal deaths and abortion? How does the virus interact with cells and affect biologic responses? What is the best vaccine? What genetic determinants govern pathogenicity?
We encourage you to submit your research on EHV-1, including studies on basic biology, viral pathogenesis such as virus-host or virus-cell interactions, immunologic responses to EHV-1 infection or vaccination, characterization of new vaccines or vaccine trial, development of new methods and models to study EHV-1, and informative clinical studies or description of new clinical syndromes.
Equid Herpesvirus type-1 (EHV-1) is one of the most important pathogens infecting horses and other equidae, including donkeys and zebras. This ubiquitous virus continues to cause infectious outbreaks in horses worldwide and there are still many unanswered questions. To name a few: How and where does the virus become latent? What determines exit from latency? How does the virus modulate the immune system to replicate in the host, establish latency, and yield such short-lived immunity after vaccination? How do we predict neuropathogenecity? How do we best treat infected or exposed horses to prevent neurologic disease, neonatal deaths and abortion? How does the virus interact with cells and affect biologic responses? What is the best vaccine? What genetic determinants govern pathogenicity?
We encourage you to submit your research on EHV-1, including studies on basic biology, viral pathogenesis such as virus-host or virus-cell interactions, immunologic responses to EHV-1 infection or vaccination, characterization of new vaccines or vaccine trial, development of new methods and models to study EHV-1, and informative clinical studies or description of new clinical syndromes.
